Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

NCT00975806 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class

Stopped MTD determined sub-optimal as efficacious treatment for renal cell carcinoma.

Conditions

Interventions

Sponsor

Celgene